Treace Medical Concepts, Inc

Treace Medical Concepts, Inc(TMCI)股票分析

$4.700

+0.102 (+2.17%)收盘时

Loading chart…
High
4.860
Open
4.590
VWAP
4.71
Vol
172.39K
Mkt Cap
411.73M
Low
4.570
Amount
811.96K
EV/EBITDA, TTM
-5.56

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

AI analysis of Treace Medical Concepts, Inc (TMCI)

buy

Treace Medical Concepts Inc (TMCI) is a good buy right now at a current price of $4.65, especially considering its recent price momentum with a 5-day change of +7.14% and a year-to-date change of +86.00%. The stock's RSI is at 54.404, indicating it is neither overbought nor oversold, which suggests potential for further upside. However, the main risk is the negative earnings trend, with a reported EPS of -0.24 for Q2 2026, which reflects ongoing losses.

估值指标

The current forward P/E ratio for Treace Medical Concepts, Inc (TMCI) is 0.00, compared to its 5-year average forward P/E of -24.32.

Forward P/E

Fair
5Y Average P/E
-24.32
Current P/E
0.00
高估
1.05
低估
-49.69

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
51.07
Current EV/EBITDA
-5.56
高估
520.28
低估
-418.13

Forward P/S

Fair
5Y Average P/S
4.33
Current P/S
1.35
高估
7.46
低估
1.21

Alphio AI Price Scenarios for TMCI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TMCI

$6.51

情景价格

B

Base

Base · 50%TMCI

$5.93

情景价格

B

Bear

Bear · 25%TMCI

$4.95

情景价格

Whales holding TMCI

A

Armistice Capital LLC

+ HoldingTMCI

+16.99%

3M Return

事件时间线

2026-08-07 (ET)

07:30:00

Company Raises 2026 Revenue Guidance to $204M-$212M

07:30:00

Treace Medical Reports Q2 Revenue of $45.38M

2026-06-18 (ET)

07:30:00

Treace Medical Successfully Completes First HyperPlate XM Implant Case

2026-05-08 (ET)

07:20:00

Treace Medical Reports Q1 Revenue of $47.2M

07:20:00

Treace Expects FY26 Adjusted EBITDA of $4M-$6M

资讯

TMCI FAQ — answered by Alphio AI

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Treace Medical Concepts Inc (TMCI) is a good buy right now at a current price of $4.65, especially considering its recent price momentum with a 5-day change of +7.14% and a year-to-date change of +86.00%. The stock's RSI is at 54.404, indicating it is neither overbought nor oversold, which suggests potential for further upside. However, the main risk is the negative earnings trend, with a reported EPS of -0.24 for Q2 2026, which reflects ongoing losses.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始